Skip to main content

Table 1 Summarizing significant changes in time-dependent regulation of MAPK/Erk1/2 and Akt/GSK-3 pathways, in nuclei and cytosol from PFC/FC and HPC of vehicle (VHE) or agomelatine (AGO) treated rats, sacrificed 1 h or 16 h after last injection

From: Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine

Protein (figure number) Brain area Subcellular fraction Variable F statistic 2 Way ANOVA P value Significant Bonferroni post-hoc tests
pERK 1 (Figure 1F) PFC/FC nucleus treatment F(1,26) = 1.62 P = 0.2147 AGO 16 h vs.
time F(1,26) = 12.88 P < 0.01 AGO 1 h p < 0.05
interaction F(1,26) = 0.46 P = 0.5042
pERK 2 (Figure 1H) PFC/FC nucleus treatment F(1,26) = 4.49 P < 0.05 AGO 16 h vs.
time F(1,26) = 18.55 P < 0.001 AGO 1 h p < 0.01
interaction F(1,26) = 0.22 P = 0.6401
pERK 1 (Figure 2F) HPC nucleus treatment F(1,26) = 2.45 P = 0.1300 VEH 16 h vs.
time F(1,26) = 28.50 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,26) = 0.13 P = 0.7201 AGO 16 h vs.
AGO 1 h p < 0.001
pERK 2 (Figure 2H) HPC nucleus treatment F(1,26) = 3.24 P = 0.0833 VEH 16 h vs.
time F(1,26) = 31.72 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,26) = 0.11 P = 0.7476 AGO 16 h vs.
AGO 1 h p < 0.001
pThr308 Akt (Figure 3B) PFC/FC nucleus treatment F(1,28) = 0.61 P = 0.4429 VEH 16 h vs.
time F(1,28) = 17.43 P < 0.001 VEH 1 h p < 0.001
interaction F(1,28) = 2.00 P = 0.1685
pSer473 Akt (Figure 3C) PFC/FC nucleus treatment F(1,28) = 5.96 P < 0.05 VEH 16 h vs.
time F(1,28) = 21.54 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.00 P = 0.9631 AGO 16 h vs.
AGO 1 h p < 0.01
pSer9 GSK-3β (Figure 3F) PFC/FC nucleus treatment F(1,28) = 0.00 P = 0.9779 VEH 16 h vs.
time F(1,28) = 22.06 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.09 P = 0.7695 AGO 16 h vs.
AGO 1 h p < 0.01
pSer473 Akt (Figure 4C) PFC/FC cytosol treatment F(1,28) = 4.15 P = 0.0512 VEH 16 h vs.
time F(1,28) = 8.33 P < 0.01 VEH 1 h p < 0.05
interaction F(1,28) = 0.22 P = 0.6429
pTyr216 GSK-3 β (Figure 4E) PFC/FC cytosol treatment F(1,28) = 2.87 P = 0.1016 AGO 16 h vs.
time F(1,28) = 12.54 P < 0.05 AGO 1 h p < 0.05
interaction F(1,28) = 0.25 P = 0.6183
pThr308 Akt (Figure 5B) HPC nucleus treatment F(1,28) = 0.46 P = 0.5017 VEH 16 h vs.
time F(1,28) = 21.92 P < 0.0001 VEH 1 h p < 0.01
interaction F(1,28) = 0.34 P = 0.5669 AGO 16 h vs.
AGO 1 h p < 0.05
pSer473 Akt (Figure 5C) HPC nucleus treatment F(1,28) = 0.86 P = 0.3626 AGO 16 h vs.
time F(1,28) = 14.89 P < 0.001 AGO 1 h p < 0.01
interaction F(1,28) = 0.29 P = 0.5928
Akt tot (Figure 6A) HPC cytosol treatment F(1,28) = 0.30 P = 0.5863 -
time F(1,28) = 6.19 P < 0.05
interaction F(1,28) = 0.18 P = 0.6777
pThr308 Akt (Figure 6B) HPC cytosol treatment F(1,28) = 1.34 P = 0.2567 VEH 16 h vs.
time F(1,28) = 9.61 P < 0.01 VEH 1 h p < 0.05
interaction F(1,28) = 0.22 P = 0.6447
pSer473 Akt (Figure 6C) HPC cytosol treatment F(1,28) = 0.52 P = 0.4788 AGO 16 h vs.
time F(1,28) = 8.33 P < 0.01 AGO 1 h p < 0.01
interaction F(1,28) = 4.75 P < 0.05
  1. Significant effects are highlighted in bold.